The Pill That Just Cut the Deadliest Cancer's Death Risk by 60% Finally Got FDA's Yes

A once-daily cancer pill that cut the risk of death by 60 per cent in patients with advanced pancreatic cancer has been approved in the US, nearly doubling median survival compared with standard chemotherapy.

The FDA cleared Rasonque, also known as Daraxonrasib, on Wednesday for adults with previously treated metastatic pancreatic ductal adenocarcinoma, offering a new option for people facing one of the world's deadliest cancers.

In the pivotal trial, patients taking the pill lived for a median of 13.2 months, compared with 6.7 months for those receiving standard chemotherapy. The drug is the first approved treatment designed to target multiple forms of RAS, a protein that drives tumour growth in most pancreatic cancers.

The approval marks a major moment in pancreatic cancer treatment, a disease with few effective options once it has spread. It also came months ahead of schedule after the FDA used its National Priority Voucher programme to accelerate the review.

A Major Survival Advantage for Patients

The approval follows results from a randomised, open-label clinical trial involving 500 adults with previously treated metastatic pancreatic adenocarcinoma. Patients receiving Daraxonrasib had a median overall survival of 13.2 months, compared with 6.7 months among those given standard chemotherapy.

That translated into a 60 per cent reduction in the relative risk of death, a result described as unprecedented in this particularly difficult-to-treat form of cancer. The findings are significant because metastatic pancreatic cancer has historically offered patients limited treatment options once the disease has progressed following initial therapy.

Pancreatic cancer is among the deadliest major cancers, partly because it is frequently diagnosed after it has already spread. In the US, about 67,000 new pancreatic cancer cases are expected each year, with pancreatic adenocarcinoma accounting for roughly 90 to 95 per cent of them.

How the New Pill Targets RAS

Daraxonrasib is designed to interfere with RAS, a family of proteins involved in signalling that can encourage cancer cells to grow and survive.

RAS mutations are found in most pancreatic adenocarcinomas, making the pathway an important target for researchers.

The FDA describes Rasonque as a first-in-class targeted treatment capable of inhibiting multiple forms of RAS.

For decades, RAS was considered one of the most difficult cancer-driving proteins to target effectively. The development of Daraxonrasib is a notable step in efforts to turn RAS inhibition into a practical cancer treatment.

The drug had already received Breakthrough Therapy and Orphan Drug designations from the FDA, while its application was granted Priority Review.

Approval Arrived Months Ahead of Deadline

The agency said the approval was issued 6.5 months before the user-fee deadline, following an accelerated review under the Commissioner's National Priority Voucher pilot programme. The programme is intended to speed up reviews of treatments addressing major public health needs.

The FDA had also allowed expanded access to the investigational treatment before its formal approval, allowing some seriously ill patients to receive the drug under applicable regulations.

Side Effects and Safety Questions

Rasonque is not without risks. The FDA lists rash, diarrhoea, inflammation of the mouth, nausea, fatigue, vomiting, abdominal pain, swelling, reduced appetite and haemorrhage among the most common side effects.

The approval does not mean the drug is a cure for pancreatic cancer. Instead, it gives doctors another treatment option for patients whose disease has already advanced and who have exhausted, or cannot tolerate, certain existing therapies.

Doubling median survival in a previously treated metastatic population marks a notable development for a cancer that is difficult to treat and could help steer future research into treatments targeting RAS-driven cancers.